Klaria’s board of directors announces that CEO Jesper Wiklund leaves the company
The board of Klaria Pharma Holding AB (publ) announces that Jesper Wiklund is leaving the CEO position to focus on other activities based in Germany. Fredrik Hübinette, the company’s chairman of the board, will assume the position as acting CEO with immediate effect during a transition period.
During the autumn, Klaria has intensified the work of identifying and signing agreements with one or more partners for the company’s migraine product Sumatriptan Alginate Film. At the same time, the process of obtaining market approval for the product continues, and the company expects to obtain market approvals in several European markets during the second half of 2024.
The R&D collaborations with Imbrium Therapeutics (Adrenaline/Epinephrine Alginate Film against allergic shock), Fluimed (Sirolimus Alginate Film against organ rejection during transplantation) and PharmaMar (currently undisclosed substance) are also proceeding according to plan. Klaria expects to be able to report results from these R&D collaborations during the first half of 2024.
“It feels exciting and inspiring that we are now finally able to offer our first product to potential commercial partners around the world. We feel confident about the product’s potential in the global migraine market as the data obtained from the clinical program exceeded our expectations, and we have received an external evaluation by L.E.K. which estimates the product’s peak sales at over USD 500 million,” says Fredrik Hübinette, Klaria’s chairman of the board.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Fredrik Hübinette, chairman of the board, Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99
This information is such that Klaria Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2023-10-25 16:00 CEST.
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses.
Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([email protected], +46(0) 8-528 00 399) for Klaria Pharma Holding AB.
For more information, see www.klaria.com.
